表紙
市場調查報告書

現代細胞療法和基因療法領域的競爭狀況分析

Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations

出版商 Frost & Sullivan 商品編碼 951769
出版日期 內容資訊 英文 46 Pages
商品交期: 最快1-2個工作天內
價格
現代細胞療法和基因療法領域的競爭狀況分析 Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations
出版日期: 2020年07月07日內容資訊: 英文 46 Pages
簡介

本報告重點介紹了CAR-T細胞治療領域的重要動向,並全面分析了技術,知識產權,投資狀況等。我們將在關注主要增長機會的同時分析競爭格局。

內容

第1章執行摘要

  • 研究重點:啟用嵌合抗原受體(CAR)T細胞療法的新技術
  • 分析框架
  • 調查方法:成功的五個步驟
  • 支持敗血症診斷的技術創新重大發現

第2章技術快照

  • 提高細胞療法和基因療法的批准速度
  • 基因治療的法規和道德觀點
  • 對精確醫療策略的需求增加
  • 製造是主要瓶頸
  • 第二代嵌合抗原受體在細胞治療領域佔據主導地位
  • CD-19是同種異體CAR-T治療的最常見靶抗原

第3章新專利情況

  • CAR-T細胞療法的專利批准量穩步增長
  • 賓夕法尼亞大學和諾華公司共同領導CAR-T細胞療法的專利領域
  • 中美共同引領CAR-T細胞療法專利領域
  • 主要專利批准摘要:Novartis
  • 獲得專利批准的關鍵快照:Cellectis,BlueBird Bio

第4章投資情況分析

  • 全球生命科學領域的重大併購趨勢
  • 基因治療-風險投資資金評估
  • 基因療法-評估主要製藥公司的許可協議
  • 戰略考慮:細胞療法和基因療法,病毒載體CMO

第5章競爭態勢分析

  • Allogene Therapeutics
  • Precision BioSciences Inc.
  • CRISPR Therapeutics AG
  • Cellectis S.A.
  • Celyad
  • Bristol-Myers Squibb (BMS)
  • Gilead
  • Novartis
  • BlueBird Bio
  • 評分方法概述
  • 每個公司的競爭分析

第6章CAR-T細胞療法:生長機會

  • 增長機會:實體瘤的CAR-T細胞療法

第7章在行業中具有重要影響力的力量

目錄
Product Code: D95F

Emerging Chimeric Antigen Receptor (CAR) T-cell Therapy Platforms

This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform

Table of Contents

1.0 EXECUTIVE SUMMARY

  • 1.1 Research Focus: Emerging Technologies Enabling chimeric antigen receptor (CAR) T-cell Therapies
  • 1.2 Analysis Framework: Frost & Sullivan Core Value
  • 1.3 Research Methodology: Five Steps Toward Success
  • 1.4 Key Findings of Technology Breakthrough Driving Sepsis Diagnosis

2.0 Technology Snapshot

  • 2.1 Rising Pace of Cell and Gene Therapy Approvals
  • 2.2 Regulatory and Ethical Perspectives on Gene Therapy
  • 2.3 Rising Demand for Precision Medicine Strategies
  • 2.4 Manufacturing Continues to be the Key Bottle Neck
  • 2.5 II Generation Chimeric Antigen ReceptorS Likely to Dominate the Cell Therapy Landscape in the Future
  • 2.6 CD-19 is the Most Common Target Antigen for Allogeneic CAR-T Therapies

3.0 Emerging Patent Landscape

  • 3.1 Steady Increase in Patent Grants for CAR-T Cell Therapies
  • 3.2 University of Pennsylvania and Novartis Lead the Patent Landscape for CAR-T Cell Therapies
  • 3.3 China and the US Lead the Patent Landscape for CAR-T Cell Therapies
  • 3.4 Snapshot of Key Patent Grants: Novartis
  • 3.5 Snapshot of Key Patent Grants: Cellectis and BlueBird Bio

4.0 Analysis of the Investment Landscape

  • 4.1 Key M&A Trends Across the Global Life Sciences Sector
  • 4.2 Gene Therapy - Venture Capital Funding Assessment
  • 4.3 Gene Therapy - Big Pharma In-licensing Deals Assessment
  • 4.4 Strategic Insights: Cell Therapies and Gene Therapies, Viral Vector CMOs

5. Analysis of the Competitive Landscape

  • 5.1 Allogene Therapeutics
  • 5.2 Precision BioSciences Inc.
  • 5.3 CRISPR Therapeutics AG
  • 5.4 Cellectis S.A.
  • 5.5 Celyad
  • 5.6 Bristol-Myers Squibb (BMS)
  • 5.7 Gilead
  • 5.8 Novartis
  • 5.9 BlueBird Bio
  • 5.10 Summary of the Scoring Methodology
  • 5.11 Competitive Analysis of CAR-T Participants

6.0 CAR-T Cell Therapies: Growth Opportunity Universe

  • 6.1 Growth Opportunity: CAR-T for Solid tumors, 2020
  • 6.2 Growth Opportunity: CAR-T for Solid tumors, 2020

7.0 Industry Influencers

  • Key Contacts
  • Key Contacts
  • Legal Disclaimer